Table 5.
Tumor mutation burden (TMB) of the prospective cohort. Mucinous (MC, n = 9) tumors have higher TMB versus adenocarcinoma cancers (AC, n = 5), p=0.07.
| Number of patients | Average TMB (mut/megabase) | High TMB∗ | Low TMB∗ | |
|---|---|---|---|---|
| Mucinous | 9 | 43.07 | 3, 33% | 6, 66% |
| Mucinous BRCA mut | 4 | 84.03 | 2, 50% | 2, 50% |
| Mucinous BRCA WT | 5 | 10.3 | 1, 20% | 4, 80% |
|
| ||||
| Adenocarcinoma | 5 | 5.9 | 0, 0% | 5, 100% |
| Adenocarcinoma BRCA mut | 2 | 4.91 | 0, 0% | 2, 100% |
| Adenocarcinoma BRCA WT | 3 | 6.56 | 0, 0% | 3, 100% |
∗Number of patients, % of patients with high/intermediate/low TMB. ∗∗High TMB using standard cutoff of >20.